BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst Pharmaceuticals (BCRX) has granted restricted stock units (RSUs) to seven newly-hired employees as employment inducements. The compensation committee approved RSUs covering 47,250 shares of BioCryst common stock, effective June 2, 2025. These equity awards, granted under Nasdaq Listing Rule 5635(c)(4), will vest over four years in equal annual installments, starting from the one-year anniversary of the grant date. The vesting is contingent upon continued employment with BioCryst. The RSUs are governed by BioCryst's Inducement Equity Incentive Plan and individual RSU agreements.

News Market Reaction

+4.29%

1 alert

+4.29% News Effect

On the day this news was published, BCRX gained 4.29%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 47,250 shares of BioCryst common stock. The RSUs were granted as of June 2, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO^® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

FAQ

How many RSUs did BioCryst (BCRX) grant to new employees in June 2025?

BioCryst granted RSUs covering 47,250 shares of common stock to seven newly-hired employees.

What is the vesting schedule for BioCryst's June 2025 RSU grants?

The RSUs vest in four equal annual installments, beginning on the one-year anniversary of the June 2, 2025 grant date.

Under which Nasdaq rule were BioCryst's June 2025 RSUs granted?

The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.

What conditions apply to BioCryst's June 2025 RSU grants?

The RSUs are subject to continued employment with BioCryst, the company's Inducement Equity Incentive Plan, and individual RSU agreements.